{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:40:20Z","timestamp":1790642420686,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ijantimicag.2020.106270","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T08:49:47Z","timestamp":1611046187000},"page":"106270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients"],"prefix":"10.1016","volume":"57","author":[{"given":"B\u00e1rbara","family":"Balandin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Ruiz de Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"L\u00f3pez-Vergara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Pintado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milagros","family":"Sancho-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cruz","family":"Soriano-Cuesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"P\u00e9rez-Pedrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jos\u00e9","family":"Asensio-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inamculada","family":"Fern\u00e1ndez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Rodr\u00edguez-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-2356","authenticated-orcid":false,"given":"Marta","family":"Chicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyes","family":"Iranzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Mart\u00ednez-Sagasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Royuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2020.106270_bib0001","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/QCO.0000000000000505","article-title":"Rational approach in the management of Pseudomonas aeruginosa infections","volume":"31","author":"Bassetti","year":"2018","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0002","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/infdis\/jiw299","article-title":"Host and pathogen biomarkers for severe Pseudomonas aeruginosa infection","volume":"215","author":"Juan","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0003","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10096-018-3428-y","article-title":"A global priority list of the TOp TEn resistant microorganism (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis","volume":"28","author":"Rello","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0004","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212527","article-title":"How to manage Pseudomonas aeruginosa infections","volume":"7","author":"Bassetti","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0005","first-page":"78","article-title":"Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish Society of Chemotherapy","volume":"31","author":"Mensa","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0006","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11908-018-0629-6","article-title":"Multidrug-resistant Pseudomonas infections: Hard to treat, but hope in the horizon?","volume":"20","author":"Nguyen","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0007","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations","volume":"63","author":"Van Dui","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0008","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane\/tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0009","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results of a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\/tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106270_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02291-19","article-title":"Real-world experience with ceftolozane-tazobactam for multidrug-resistant Gram-negative bacterial infections","volume":"64","author":"Jorgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1178633720905977","article-title":"Experience with ceftolozane-tazobactam for the treatment of serious Pseudomonas aeruginosa infections in Saudi tertiary care center","volume":"13","author":"Bosaeed","year":"2020","journal-title":"Infect Dis (Auckl)"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0013","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa: infections: a multicentre nationwide clinical experience","volume":"54","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106270_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02340-18","article-title":"A case-control study of real-life experience with ceftolozane-tazobactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection","volume":"63","author":"Fern\u00e1ndez-Cruz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0015","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10096-018-3361-0","article-title":"Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas: experience from the Balearic Islands 2018","volume":"11","author":"D\u00edaz-Ca\u00f1estro","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0016","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escol\u00e1-Verg\u00e9","year":"2018","journal-title":"Infections"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0017","first-page":"1","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"31","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jgar.2018.01.010","article-title":"Clinical experience with ceftolozane\/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa","volume":"13","author":"Xipell","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0019","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Disease"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0021","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","article-title":"APACHE II: a severity of disease classification system","volume":"13","author":"Knaus","year":"1985","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0022","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s001340050931","article-title":"The use of maximum SOFA score to quantify organ dysfunction\/failure in intensive care. Results of a prospective multicentre study. Working group on sepsis related problems of the ESICM","volume":"25","author":"Moreno","year":"1999","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/0196-6553(88)90053-3","article-title":"CDC definitions for nosocomial infections","volume":"16","author":"Garner","year":"1988","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0024","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0025","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S1473-3099(17)30228-1","article-title":"Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study","volume":"17","author":"Guti\u00e9rrez-Guti\u00e9rrez","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0026","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.566","article-title":"Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia","volume":"56","author":"Xiao","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0027","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis and management","volume":"356","author":"Edwars","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0028","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. 2017. Breakpoint tables for interpretation of MICs and zone diameters, version 7.1. http:\/\/www.eucast.org."},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0029","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0030","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/aje\/kwf215","article-title":"Statistical analysis of correlated data using generalized estimating equations: an orientation","volume":"15","author":"Hanley","year":"2003","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0031","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijantimicag.2019.02.004","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered in intensive care unit in Spain: the SUPERIOR multicentre study","volume":"53","author":"Garc\u00eda-Fern\u00e1ndez","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0032","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1093\/jac\/dkz030","article-title":"High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial","volume":"74","author":"P\u00e9rez","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2020.106270_bib0033","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology","volume":"74","author":"Del Barrio-Tofi\u00f1o","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106270_bib0034","first-page":"32","article-title":"Epidemiology and treatment of multidrug-resistant and extensively resistant drug-resistant Pseudomonas aeruginosa infections","volume":"28","author":"Horcajada","year":"2019","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106270_bib0035","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1002\/ajh.25379","article-title":"Drug-induced thrombocytopenia: 2019 Update of clinical and laboratory data","volume":"94","author":"Mitta","year":"2019","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.ijantimicag.2020.106270_bib0036","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/WNL.0000000000002023","article-title":"Seizures as adverse events of antibiotic drugs: A systematic review","volume":"85","author":"Sutter","year":"2015","journal-title":"Neurology"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920304982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:39:03Z","timestamp":1760377143000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920304982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0924857920304982"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106270","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106270","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106270"}}